VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
Portfolio Pulse from
VistaGen Therapeutics, Inc. (VTGN) reported a Q2 loss of $0.42 per share, missing the Zacks Consensus Estimate of a $0.40 loss. This is an improvement from the $0.66 loss per share a year ago.
November 08, 2024 | 1:45 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
VistaGen Therapeutics reported a Q2 loss of $0.42 per share, missing the expected loss of $0.40. Despite missing estimates, the loss is an improvement from the previous year's $0.66 per share.
The company's reported loss per share was worse than expected, which is typically negative for stock prices. However, the loss is smaller than the previous year, indicating some improvement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100